Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.525
+0.025 (1.00%)
At close: Nov 4, 2024, 4:00 PM
2.650
+0.125 (4.95%)
After-hours: Nov 4, 2024, 6:19 PM EST
Galectin Therapeutics Employees
Galectin Therapeutics had 14 employees as of December 31, 2023. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change (1Y)
2
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,430,929
Market Cap
157.25M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
biote | 194 |
Tenaya Therapeutics | 140 |
Alpha Tau Medical | 121 |
Adverum Biotechnologies | 121 |
Lineage Cell Therapeutics | 75 |
Verastem | 73 |
Vigil Neuroscience | 69 |
Compugen | 68 |
GALT News
- 20 days ago - Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - GlobeNewsWire
- 2 months ago - Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update - GlobeNewsWire
- 3 months ago - Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer - GlobeNewsWire
- 5 months ago - Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress - GlobeNewsWire
- 6 months ago - Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update - GlobeNewsWire
- 7 months ago - Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point - Seeking Alpha